ClinicalTrials.gg

Program

sevabertinib

Also written as “BAY2927088”, “Sevabertinib” and “Sevabertinib (BAY 2927088)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Hepatic Insufficiency, led by Bayer.

Furthest: phase 3, since Jun 5, 20248 company-led studies, 2 open or runningNext primary completion: Oct 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer82 open or runningphase 3since Jun 5, 2024Jan 15, 2024Oct 28, 2027phase 3 · NCT06452277

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2024First study: phase 1 study in Advanced Non-small Cell Lung CancerFirst studyNCT06221475 · 8 enrolled · Netherlands
  2. Mar 19, 20242 phase 1 studies in Advanced Non-small Cell Lung CancerNCT06378658, NCT06329895
  3. Apr 7, 2024Phase 1 study in Advanced Non-small Cell Lung CancerNCT06360211 · 15 enrolled · United States
  4. Jun 5, 2024Phase 3 study in Advanced Non-small Cell Lung Cancer, HER2 MutationNCT06452277 · 444 planned · United States, Argentina, Australia and more
  5. Dec 18, 2024Phase 2 study in Colorectal NeoplasmsNCT06760819 · 111 planned · United States, Australia, Canada and more
  6. Jul 18, 2025Phase 1 study in Hepatic InsufficiencyNCT07102095 · 18 enrolled · United States
  7. Aug 4, 2026Phase 1 study in Healthy ParticipantsNCT07753252 · 42 enrolled · United States

Ahead

  1. Oct 28, 2027Primary completion: phase 3 study in Advanced Non-small Cell Lung Cancer, HER2 MutationNCT06452277
  2. Feb 2, 2029Primary completion: phase 2 study in Colorectal NeoplasmsNCT06760819

TargetBeta

EGFR →ERBB2 →read by rule
“An orally bioavailable, mutant-selective, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
sunvozertinibruleDizal Pharmaceuticalsphase 312
enozertinibruleoric-pharmaceuticalsphase 23
EGFR/HER2 Mutant-selective Inhibitor BH-30643ruleblossomhill-therapeuticsphase 21
GENSCI139ruleChangchun GeneScience Pharmaceuticalphase 11

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07753252Healthy Participants · United States1CompletedOct 8, 202642
NCT07102095Hepatic Insufficiency · United States1CompletedDec 3, 202518
NCT06760819Colorectal Neoplasms · United States, Australia, Canada and more2RecruitingFeb 2, 2029111
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation · United States, Argentina, Australia and more3RecruitingOct 28, 2027444
NCT06360211Advanced Non-small Cell Lung Cancer · United States1CompletedJun 28, 202415
NCT06378658Advanced Non-small Cell Lung Cancer · United States1CompletedJun 11, 202421
NCT06329895Advanced Non-small Cell Lung Cancer · United Kingdom1CompletedJun 10, 202415
NCT06221475Advanced Non-small Cell Lung Cancer · Netherlands1CompletedApr 5, 20248

How it is read

Names in the registry

  • “BAY2927088”, 4 entries
  • “Sevabertinib”, 2 entries
  • “Sevabertinib (BAY 2927088)”, 1 entry
  • “BAY2927088 coated tablet 10 mg”, 1 entry
  • “[14C]-BAY2927088 solution for infusion”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.